Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Esophageal Neoplasms 25Rectal Neoplasms 23Glioblastoma 23Prostatic Neoplasms 19Carcinoma, Non-Small-Cell Lung 17Breast Neoplasms 17Pancreatic Neoplasms 16Lung Neoplasms 16Squamous Cell Carcinoma of Head and Neck 14Head and Neck Neoplasms 14Neoplasms 12Oropharyngeal Neoplasms 11Neoplasm Metastasis 10Esophageal Squamous Cell Carcinoma 9Adenocarcinoma Of Esophagus 8Uterine Cervical Neoplasms 7Glioma 7Triple Negative Breast Neoplasms 6Stomach Neoplasms 6Gliosarcoma 6Carcinoma, Squamous Cell 6Brain Neoplasms 6Urinary Bladder Neoplasms 5Nasopharyngeal Carcinoma 5Melanoma 5Laryngeal Neoplasms 5Colorectal Neoplasms 5Xerostomia 4Sarcoma 4Mouth Neoplasms 4

Interventions

Gemcitabine 13Doxorubicin 8Docetaxel 7Trabectedin 5pazopanib 4Nivolumab 4Temozolomide 3Specimen Handling 3Sorafenib 3rucaparib 2pembrolizumab 2liposomal doxorubicin 2durvalumab 2brostallicin 2Sunitinib 2Radiotherapy 2Radiation Dose Hypofractionation 2Magnetic Resonance Spectroscopy 2Letrozole 2Ifosfamide 2Dacarbazine 2Bevacizumab 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2tremelimumab 1talimogene laherparepvec 1sotigalimab 1soblidotin 1saracatinib 1rubitecan 1romidepsin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leiomyosarcoma × Radiation × Clear all
NCT02923778 2026-05-13

Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡